Monitoring with anti-idiotypic sera has been applied to identify tumoral cells in a myeloma patient still alive in complete remission 9 years after diagnosis. Monoclonal plasma cells displayed a labeling index that decreased in complete remission below 1 %. The great majority of B lymphocytes belonged to the tumoral clone even in complete remission and were therefore not affected by conventional chemothrapy. Some aspects of this myeloma patient are discussed in the light of these immunologic and kinetic findings. In addition, it is suggested that the therapeutic management of the complete remission should be re-examined, by considering a lymphocytolytic therapy.
Get full access to this article
View all access options for this article.
References
1.
AlexanianR., SalmonS.E., BonnetJ., GehanE., HautA., WeickJ.: Chemotherapy for multiple myeloma. In: Recent Advances in Cancer Treatment.TagnonH.J., and StaquetM.J. (Eds.), pp. 19–38, Raven Press, New York, 1977.
2.
BoccadoroM., Van AckerA., PileriA., UrbainJ.: Idiotypic lymphocytes in human monoclonal gammaphathies.Ann. Immunol. (Paris), 132C, 9–19, 1981.
3.
ConteP.F., BoccadoroM., PileriA.: Early B lymphocytes in man.Experientia, 36: 1124–1125, 1980.
4.
DurieB.G., SalmonS.E., MoonT.E.: Pretreatment tumor mass, cell kinetics and prognosis in multiple myeloma.Blood, 55: 364–372, 1980.
5.
DurieB.G., RussellD.H., SalmonS.E.: Reappraisal of plateau phase in myeloma.Lancet, 2: 65–68, 1980.
6.
KyleA.: Monoclonal gammopathies of undetermined significance.Natural history in 241 cases. Am. J. Med., 64: 814–826, 1978.
7.
KubagawaH., VoglerL., CapraJ.D., ConradM.E., LawtonA., CooperM.D.: Studies on the clonal origin of multiple myeloma.Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B cell differentiation. J. Exp. Med., 150: 792–807, 1979.
8.
LindströmF.D., HardlyW.R., EberleB.J., WilliamsR.C.: Multiple myeloma and benign monoclonal gammopathy: Differentiation by immunofluorescence of B lymphocytes.Ann. Intern. Med., 78: 837–844, 1973.
9.
NortonL., SimonR.: Tumor size, sensitivity to therapy and design of treatment schedules.Cancer Treat. Rep., 61: 1307–1317, 1977.
10.
PileriA., TaroccoR.C.: In vivo kinetic studies in human myeloma.Haematologica, 59: 10–24, 1974.
11.
SalmonS.E., SmithB.A.: Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma.J. Clin. Invest, 49: 1114–1121, 1970.
12.
Van AckerA., ConteF., HulinN., UrbainJ.: Idiotypic studies on myeloma B cells.Eur. J. Cancer, 15: 627–635, 1979.
